4D Molecular Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $FDMT in the last 7 days.
Ocular Therapeutix (OCUL) and 4D Molecular (FDMT) shares rose after EyePoint Pharmaceuticals (EYPT) reported its DURAVYU trial missed its primary goal. Clear Street maintained a 'Buy' rating on OCUL, while B. Riley set a $37 target for FDMT. EYPT's stock fell 67% on the news, with OCUL and FDMT gaining 6% and 19% respectively.
Kirn David (See Remarks) sold 69,076 shares of 4D Molecular Therapeutics, Inc. (FDMT) at an average of $15.75 ($15.36–$16.42, $1.09M total) across 2 trades on 2026-08-19 under a Rule 10b5-1 trading plan.
Ocular Therapeutix (OCUL) and 4D Molecular (FDMT) rose after EyePoint Pharmaceuticals (EYPT) said its DURAVYU late-stage wet AMD trial missed its main goal versus Eylea. Analysts cited potential competitive relief for OCUL’s Axpaxli and trial design benefits for FDMT’s 4D-150. OCUL gained 6%, FDMT 19%; EYPT shares fell 67%.
Recent FDMT coverage spans market movers, insider activity and technology.
In the last 30 days, FDMT insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($1.1M). The most active reporter was Bizily Scott, Chief Legal Officer, with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Strong upside potential from favorable comparative trial data.
The insider sale may signal modest downside pressure but size is small relative to float.
FDMT gets a direct trial-design read-through benefit from EyePoint’s adverse subgroup outcomes.
Near-term upside bias from Phase 3 execution and new $200M credit facility, but dilution and cash burn remain key risks.
The filing adds concrete near-to-midterm catalysts (Phase 3 topline windows, DME Phase 3 initiation timing) and extends cash runway via a new Hercules credit facility.
alphai scores every news story that mentions FDMT with an AI model for sentiment and relevance, and aggregates insider trades from 4D Molecular Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ocular Therapeutix (OCUL) and 4D Molecular (FDMT) shares rose after EyePoint Pharmaceuticals (EYPT) reported its DURAVYU trial missed its primary goal. Clear Street maintained a 'Buy' rating on OCUL, while B. Riley set a $37 target for FDMT. EYPT's stock fell 67% on the news, with OCUL and FDMT gaining 6% and 19% respectively.
2 min readKirn David (See Remarks) sold 69,076 shares of 4D Molecular Therapeutics, Inc. (FDMT) at an average of $15.75 ($15.36–$16.42, $1.09M total) across 2 trades on 2026-08-19 under a Rule 10b5-1 trading plan.
1 min readOcular Therapeutix (OCUL) and 4D Molecular (FDMT) rose after EyePoint Pharmaceuticals (EYPT) said its DURAVYU late-stage wet AMD trial missed its main goal versus Eylea. Analysts cited potential competitive relief for OCUL’s Axpaxli and trial design benefits for FDMT’s 4D-150. OCUL gained 6%, FDMT 19%; EYPT shares fell 67%.
5 min readBiotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.
7 min read4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones • Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 • 4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027 • Prese
6 min read4D Molecular Therapeutics reported positive 2-year results from its phase 2b PRISM trial of 4D-150 for wet age-related macular degeneration. The company said the study showed sustained BCVA and OCT central subfield thickness improvements and reduced treatment burden versus projected on-label aflibercept. Safety was described as well tolerated, with 2.8% mild transient inflammation. Phase 3 topline data is expected in 2027.
4 min read4D Molecular Therapeutics (FDMT) shares rose after Phase 2b results for 4D-150 in wet AMD. In 45 patients, the 3E10 vg/eye dose was chosen for Phase 3. As of May 18, 2026, it maintained visual acuity and reduced treatment burden 78% vs projected aflibercept injections, with 2.8% mild inflammation. Phase 3 enrollment completed; topline expected 2027. HC Wainwright reiterated Buy, $36 target.
4 min readKirn David (See Remarks) sold 58,333 shares of 4D Molecular Therapeutics, Inc. (FDMT) at an average of $12.64 ($12.01–$12.87, $0.74M total) across 3 trades over 2026-07-09 to 2026-07-10 under a Rule 10b5-1 trading plan.
2 min read4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001650648 0001650648 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24,
4 min readKirn David (See Remarks) sold 114,746 shares of 4D Molecular Therapeutics, Inc. (FDMT) at $10.47 ($1.20M total) on 2026-06-22 under a Rule 10b5-1 trading plan.
2 min read
